BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
申请人:AMGEN INC.
公开号:US20160046626A1
公开(公告)日:2016-02-18
The present invention provides compounds of Formula I,
and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
[EN] BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS<br/>[FR] COMPOSÉS DE SULFONAMIDES BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU CANAL SODIQUE
申请人:AMGEN INC
公开号:WO2014201206A1
公开(公告)日:2014-12-18
The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
Bicyclic sulfonamide compounds as sodium channel inhibitors
申请人:AMGEN INC.
公开号:US09212182B2
公开(公告)日:2015-12-15
The present invention provides compounds of Formula I,
and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.